HHV-6 and Lyme Disease: The Co-Reactivation Problem

At a Glance

The Hidden Virus Making Lyme Symptoms Worse

You have been treating Lyme disease for months. The joint pain improved. The flu-like symptoms resolved. But the brain fog persists. The fatigue is still crushing. The neuropathy has not budged. Your Lyme markers are improving, but your neurological symptoms seem stuck.

Here is what I tell my patients in this situation: when antimicrobial therapy for Borrelia produces systemic improvement but neurological symptoms remain disproportionately resistant, a reactivated neurotropic virus — particularly HHV-6 — should be investigated.

What HHV-6 Is and Where It Lives

Human Herpesvirus 6 exists in two variants:

• HHV-6A: More neurotropic; associated with multiple sclerosis, encephalitis, and chronic fatigue
• HHV-6B: Causes roseola infantum (sixth disease) in children; the more common variant

Both variants infect over 90% of the population by age two. After primary infection, HHV-6 establishes latency in multiple cell types, but its most clinically significant reservoir is in the central nervous system — specifically in glial cells, astrocytes, and oligodendrocytes [1].

This CNS tropism is what makes HHV-6 particularly problematic in the context of Lyme disease. While EBV reactivation primarily drives fatigue through immune and mitochondrial mechanisms, HHV-6 reactivation directly affects the brain and nervous system.

The Lyme-HHV-6 Connection

The relationship between Lyme disease and HHV-6 reactivation is bidirectional and synergistic:

Lyme → HHV-6 reactivation:

1. Borrelia burgdorferi suppresses NK cell function and CD8+ T-cell activity
2. Borrelia outer surface proteins (OspA, VlsE) modulate complement and immune signaling
3. Reduced immune surveillance allows latent HHV-6 to shift from latent to lytic phase
4. HHV-6 reactivates preferentially in the CNS due to its neurotropic nature

HHV-6 → Worsened Lyme:

1. HHV-6 produces transactivating proteins that can enhance Borrelia gene expression
2. HHV-6 further suppresses NK cell function, reducing the immune system’s ability to clear Borrelia
3. HHV-6-mediated neuroinflammation compounds Borrelia-mediated neuroborreliosis
4. The combined immune suppression creates an environment where other viruses also reactivate (EBV, CMV, VZV)

This creates a vicious cycle: Lyme suppresses immunity → HHV-6 reactivates → HHV-6 further suppresses immunity → Lyme becomes harder to clear → more viral reactivation.

Symptoms of HHV-6 Reactivation in Lyme Patients

HHV-6 reactivation in the context of Lyme disease adds a specific neurological symptom burden on top of the baseline Lyme presentation:

Neurological (CNS tropism):

• Severe brain fog — often the most treatment-resistant symptom
• Cognitive processing speed reduction
• Word-finding difficulty
• Memory impairment (particularly working memory)
• Encephalitis-like episodes (severe headache, confusion, light sensitivity)

Neurological (peripheral):

• Neuropathic pain (burning, tingling, numbness)
• Small fiber neuropathy
• Autonomic dysfunction (POTS, temperature dysregulation)
• Seizure-like episodes (documented in severe reactivation)

Systemic:

• Profound fatigue disproportionate to other Lyme symptoms
• Low-grade fever or temperature instability
• Myalgia
• Lymphadenopathy

The distinguishing clue: When a Lyme patient’s systemic symptoms improve with anti-Borrelia therapy but neurological symptoms remain disproportionately severe, HHV-6 reactivation is a primary consideration.

The Evidence

What We Know (Human Data)

The association between HHV-6 and neurological disease is well-documented beyond the Lyme context. HHV-6 has been identified in brain tissue of patients with multiple sclerosis, encephalitis, and temporal lobe epilepsy. Its neurotropism is not controversial [1].

In the context of chronic fatigue and ME/CFS, multiple studies have documented elevated HHV-6 reactivation markers:

• A study by Chapenko et al. found active HHV-6 infection in 52% of ME/CFS patients vs. 12% of controls [2]
• Lerner et al. demonstrated clinical improvement in ME/CFS patients treated with antiviral therapy targeting HHV-6 and EBV
• A 2023 study in Viruses documented 72.5% co-expression of HHV-6 and EBV in ME/CFS patients, suggesting synergistic viral reactivation [3]

The specific Lyme-HHV-6 co-reactivation data is more limited but clinically relevant. Nicolson et al. documented multiple co-infections including HHV-6 in chronic Lyme patients, with reactivated viral infections present in the majority of patients with persistent neurological symptoms.

What I See in Practice

In our clinical experience treating over 12,000 patients with tick-borne diseases, HHV-6 reactivation is present in what I estimate to be 50-60% of patients with chronic neuroborreliosis. The percentage is highest in patients who have been ill the longest and those with concurrent mold/CIRS.

What I observe in practice is a consistent pattern: patients with the most treatment-resistant neurological symptoms almost always have viral co-reactivation. When we add antiviral therapy targeting HHV-6 to the anti-Borrelia regimen, the neurological symptoms that were plateau’d begin to improve — typically within 4-8 weeks of antiviral initiation.

I also observe that HHV-6 reactivation rarely occurs in isolation. In our patient population, patients with reactivated HHV-6 almost always also have reactivated EBV, and frequently CMV as well. This supports the immune suppression cascade model where one destabilization leads to multiple viral reactivations.

Practical Application

Testing for HHV-6 Reactivation

Standard serology:

• HHV-6 IgG — present in 90%+ of adults (indicates past infection, NOT reactivation)
• HHV-6 IgM — can indicate reactivation but has poor sensitivity
• HHV-6 IgG avidity — low avidity IgG suggests recent or active infection/reactivation

Molecular testing:

• HHV-6 PCR (blood) — detects viral DNA in peripheral blood; positive result strongly suggests active replication
• HHV-6 PCR (CSF) — most definitive for CNS reactivation, but requires lumbar puncture
• HHV-6 quantitative PCR — tracks viral load over time; useful for monitoring treatment response

Important caveat: Approximately 1% of the population has chromosomally integrated HHV-6 (ciHHV-6), where the viral genome is integrated into the host chromosome and present in every cell. These individuals will have very high HHV-6 PCR levels that do not indicate active replication. If HHV-6 PCR is extremely high (>6 log copies/mL), ciHHV-6 should be considered.

Treatment Approach

1. Continue Lyme treatment Do not stop anti-Borrelia therapy when adding antivirals. Both infections must be treated simultaneously.

2. Antiviral therapy for HHV-6

• Valganciclovir 450-900mg twice daily — the most commonly used antiviral for HHV-6. More potent against HHV-6 than acyclovir or valacyclovir. Requires CBC monitoring (can cause neutropenia and thrombocytopenia).
• Foscarnet — reserved for severe or ganciclovir-resistant cases. IV administration, significant nephrotoxicity.
• Cidofovir — another option for resistant cases. Nephrotoxic.
• Duration: 3-6 months minimum for chronic reactivation

3. Immune restoration

• Address all immune suppressors: Lyme, Bartonella, mold, stress
• NK cell function testing to guide intervention
• Thymosin alpha-1 for T-cell restoration
• Vitamin D optimization (50-80 ng/mL)
• Medicinal mushrooms (AHCC, turkey tail) for NK cell support

4. Neuroprotective support

• Lion’s mane mushroom — evidence for nerve growth factor stimulation
• Alpha-lipoic acid — neuroprotective and mitochondrial support
• Phosphatidylcholine — cell membrane and myelin support
• B12 (methylcobalamin) — critical for nerve repair

5. Monitor response

• HHV-6 PCR every 3 months
• Symptom tracking focusing on neurological domains
• CBC every 2-4 weeks during valganciclovir (monitor for neutropenia)
• Renal function monitoring with any antiviral

Safety and Considerations

• Valganciclovir has significant bone marrow toxicity. Regular CBC monitoring (every 2-4 weeks initially) is mandatory. Neutropenia requires dose reduction or treatment interruption.
• Valganciclovir is teratogenic. Contraindicated in pregnancy and for conception (both partners) during and for 90 days after treatment.
• The distinction between ciHHV-6 (chromosomally integrated) and active reactivation is clinically critical. Treating ciHHV-6 with antivirals is unnecessary and potentially harmful.
• Herxheimer-like reactions are less common with antiviral therapy than with antibacterial treatment, but can occur.
• Not all neurological symptoms in Lyme patients are caused by HHV-6. Neuroborreliosis, Bartonella neuropsychiatric infection, and autoimmune encephalitis should also be considered.

The Bottom Line

HHV-6 is the viral co-reactivation most likely to produce treatment-resistant neurological symptoms in chronic Lyme patients. Its CNS tropism means it directly affects brain fog, cognition, neuropathy, and autonomic function — the symptoms that most often persist even when anti-Borrelia therapy is otherwise effective. Testing requires more than standard serology: HHV-6 PCR and IgG avidity are the critical markers. Treatment with valganciclovir, combined with continued Lyme treatment and immune restoration, can break through the neurological plateau that defines so many chronic Lyme cases. In my clinical experience, addressing viral co-reactivation is not optional — it is an essential component of comprehensive tick-borne disease management.

References

1. Agut H, Bonnafous P, Gautheret-Dejean A. Laboratory and clinical aspects of human herpesvirus 6 infections. Clin Microbiol Rev. 2015;28(2):313-335. PMID: 25762531
2. Chapenko S, Krumina A, Logina I, et al. Association of active human herpesvirus-6, -7 and parvovirus B19 infection with clinical outcomes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Adv Virol. 2012;2012:205085. PMID: 22927850
3. Rasa-Dzelzkaleja S, Krumina A, Capenko S, et al. The persistent viral infections in the development and severity of myalgic encephalomyelitis/chronic fatigue syndrome. J Transl Med. 2023;21(1):33. PMID: 36653843
4. Nicolson GL, Haier J. Role of chronic bacterial and viral infections in neurodegenerative, neurobehavioural, psychiatric, autoimmune and fatiguing illnesses. Br J Med Pract. 2010;3(1):a305.